OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
Recruiting now · Not applicable
Conditions studied: Acute Coronary Syndrome
In brief
Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI remains debated. The OPT-CAD score is a risk stratification tool derived from Chinese patients which has been demonstrated superior predictive capabilities for ischemic events and all-cause mortality than the GRACE score. Therefore, we hypothesize that the OPT-CAD score can be used to guide the timing of the DAPT de-escalation strategy to monotherapy with P2Y12 inhibitors for ACS patients, that is, low-risk patients could be de-escalated after 1 month, while high-risk patients could be de-escalated after 3 months, so as to achieve individualized antithrombotic therapy and maximize patient benefit.
Key facts
- Study ID
- NCT06216821
- Run by
- Shenyang Northern Hospital
- People needed
- 3490
- Starts
- 2024-07-02
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2025-09-10
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients with ages of 18-80 years;
- Patients with clinically diagnosed ACS who have undergone at least one DES implantation;
- Individuals capable of completing the OPT-CAD scoring calculation;
- Researchers assessing that participants can tolerate at least a 12-month duration of DAPT therapy;
- Written informed consent provided.
You may not qualify if…
- Left main coronary artery lesion PCI;
- Allergy to study drugs such as aspirin, clopidogrel, or ticagrelor;
- Meeting 1 major or 2 minor criteria for high bleeding risk according to the ARC-HBR criteria;
- Anticipated need for revascularization or surgical intervention within 12 months;
- Severe ischemia or hemorrhage events during the current hospitalization;
- Life expectancy of other serious diseases is less than 1 year;
- Pregnant or women of childbearing age who intend to conceive within 1 year;
- Participation in other clinical trials while still under observation;
- Researchers considering ineligibility for enrollment.
Where it is running
- General Hospital of Northern Theater Command — Shenyang, Liaoning, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.